Circulating MicroRNAs As Potential New Biomarkers for Prostate Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2013 May 2

PMID 23632485

Citations 73

Authors

A Sita-Lumsden

D A Dart

J Waxman

C L Bevan

Affiliations

Soon will be listed here.

Abstract

Since they were first described in the 1990s, circulating microRNAs (miRNAs) have provided an active and rapidly evolving area of current research that has the potential to transform cancer diagnostics and therapeutics. In particular, miRNAs could provide potential new biomarkers for prostate cancer, the most common cause of cancer in UK men. Current diagnostic tests for prostate cancer have low specificity and poor sensitivity. Further, although many prostate cancers are so slow growing as not to pose a major risk to health, there is currently no test to distinguish between these and cancers that will become aggressive and life threatening. Circulating miRNAs are highly stable and are both detectable and quantifiable in a range of accessible bio fluids, thus have the potential to be useful diagnostic, prognostic and predictive biomarkers. This review aims to summarise the current understanding of circulating miRNAs in prostate cancer patients and their potential role as biomarkers.

Citing Articles

Psoriasis Treatments: Emerging Roles and Future Prospects of MicroRNAs.

Teo L, Juantuah-Kusi N, Subramanian G, Sampath P Noncoding RNA. 2025; 11(1).

PMID: 39997616 PMC: 11858470. DOI: 10.3390/ncrna11010016.

The Role of microRNA in Spermatogenesis: Is There a Place for Fertility Preservation Innovation?.

Klees C, Alexandri C, Demeestere I, Lybaert P Int J Mol Sci. 2024; 25(1).

PMID: 38203631 PMC: 10778981. DOI: 10.3390/ijms25010460.

MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients.

Lote H, Mousoullou F, Vlachogiannis G, Lampis A, Satchwell L, Peckitt C Front Oncol. 2023; 13:1258365.

PMID: 38094609 PMC: 10718572. DOI: 10.3389/fonc.2023.1258365.

Unlocking the mystery associated with infertility and prostate cancer: an update.

Mukherjee A, Gopalakrishnan A Med Oncol. 2023; 40(6):160.

PMID: 37099242 DOI: 10.1007/s12032-023-02028-3.

A novel platform using homobifunctional hydrazide for enrichment and isolation of urinary circulating RNAs.

Koo B, Kim Y, Jang Y, Liu H, Kim M, Lee H Bioeng Transl Med. 2023; 8(1):e10348.

PMID: 36684108 PMC: 9842063. DOI: 10.1002/btm2.10348.

References

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Zhang H, Yang L, Zhu Y, Yao X, Zhang S, Dai B . Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2010; 71(3):326-31. DOI: 10.1002/pros.21246. View

May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B . Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients. J Urol. 2007; 178(5):1957-62. DOI: 10.1016/j.juro.2007.07.043. View

Iguchi H, Kosaka N, Ochiya T . Secretory microRNAs as a versatile communication tool. Commun Integr Biol. 2010; 3(5):478-81. PMC: 2974086. DOI: 10.4161/cib.3.5.12693. View

Brase J, Johannes M, Schlomm T, Falth M, Haese A, Steuber T . Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2010; 128(3):608-16. DOI: 10.1002/ijc.25376. View

Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N . Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011; 32(3):583-8. DOI: 10.1007/s13277-011-0154-9. View

Shen J, Hruby G, McKiernan J, Gurvich I, Lipsky M, Benson M . Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012; 72(13):1469-77. PMC: 3368098. DOI: 10.1002/pros.22499. View

Schroder F, Roobol M . Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol. 2009; 19(3):227-31. DOI: 10.1097/MOU.0b013e328329a2d0. View

Mahn R, Heukamp L, Rogenhofer S, von Ruecker A, Muller S, Ellinger J . Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011; 77(5):1265.e9-16. DOI: 10.1016/j.urology.2011.01.020. View

10.

Kroh E, Parkin R, Mitchell P, Tewari M . Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 50(4):298-301. PMC: 4186708. DOI: 10.1016/j.ymeth.2010.01.032. View

11.

Fletcher C, Dart D, Sita-Lumsden A, Cheng H, Rennie P, Bevan C . Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer. Hum Mol Genet. 2012; 21(14):3112-27. DOI: 10.1093/hmg/dds139. View

12.

Chen Z, Zhang G, Li H, Luo J, Li Z, Chen G . A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012; 72(13):1443-52. DOI: 10.1002/pros.22495. View

13.

Bernstein E, Kim S, Carmell M, Murchison E, Alcorn H, Li M . Dicer is essential for mouse development. Nat Genet. 2003; 35(3):215-7. DOI: 10.1038/ng1253. View

14.

Kozomara A, Griffiths-Jones S . miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2010; 39(Database issue):D152-7. PMC: 3013655. DOI: 10.1093/nar/gkq1027. View

15.

Bryant R, Pawlowski T, Catto J, Marsden G, Vessella R, Rhees B . Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012; 106(4):768-74. PMC: 3322952. DOI: 10.1038/bjc.2011.595. View

16.

Cooperberg M, Pasta D, Elkin E, Litwin M, Latini D, Du Chane J . The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005; 173(6):1938-42. PMC: 2948569. DOI: 10.1097/01.ju.0000158155.33890.e7. View

17.

Selth L, Townley S, Gillis J, Ochnik A, Murti K, Macfarlane R . Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer. 2011; 131(3):652-61. DOI: 10.1002/ijc.26405. View

18.

Nicoloso M, Spizzo R, Shimizu M, Rossi S, Calin G . MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009; 9(4):293-302. DOI: 10.1038/nrc2619. View

19.

Heneghan H, Miller N, Kerin M . MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol. 2010; 10(5):543-50. DOI: 10.1016/j.coph.2010.05.010. View

20.

Gonzales J, Fink L, Goodman Jr O, Symanowski J, Vogelzang N, Ward D . Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 2011; 9(1):39-45. DOI: 10.1016/j.clgc.2011.05.008. View